RT Journal Article
SR Electronic
T1 Multi-ancestry meta-analysis and fine-mapping in Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.04.22278442
DO 10.1101/2022.08.04.22278442
A1 Lake, Julie
A1 Solsberg, Caroline Warly
A1 Kim, Jonggeol Jeffrey
A1 Acosta-Uribe, Juliana
A1 Makarious, Mary B.
A1 Li, Zizheng
A1 Levine, Kristin
A1 Heutink, Peter
A1 Alvarado, Chelsea
A1 Vitale, Dan
A1 Kang, Sarang
A1 Gim, Jungsoo
A1 Lee, Kun Ho
A1 Pina-Escudero, Stefanie D.
A1 Ferrucci, Luigi
A1 Singleton, Andrew B.
A1 Blauwendraat, Cornelis
A1 Nalls, Mike A.
A1 Yokoyama, Jennifer S.
A1 Leonard, Hampton L.
YR 2022
UL http://medrxiv.org/content/early/2022/08/11/2022.08.04.22278442.abstract
AB Genome-wide association studies (GWAS) of Alzheimer’s disease are predominantly carried out in European ancestry individuals despite the known variation in genetic architecture and disease prevalence across global populations. We leveraged published and de novo GWAS from European, East Asian, African American, and Caribbean Hispanic populations to perform the largest multi-ancestry GWAS meta-analysis of Alzheimer’s disease to date. This method allowed us to identify two independent novel disease-associated loci on chromosome 3. We also leveraged diverse haplotype structures to fine-map nine loci and globally assessed the heterogeneity of known risk factors across populations. Additionally, we compared the generalizability of multi-ancestry- and single-ancestry-derived polygenic risk scores in a three-way admixed Colombian population. Our findings highlight the importance of multi-ancestry representation in uncovering and understanding putative factors that contribute to Alzheimer’s disease risk.Competing Interest StatementK.L., D.V., H.L. and M.A.N.'s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc. P.H. is also an advisor to Neuron23 Inc. J.S.Y. serves on the scientific advisory board for the Epstein Family Alzheimer's Research Collaboration.Funding StatementThis work was supported in part by the Intramural Research Programs of the National Institute on Aging (NIA) part of the National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-NS003154, Z01-AG000949-02, ZO1-AG000535 and Z01-ES101986. J.S.Y. is supported by NIH-NIA R01 AG062588, R01 AG057234, P30 AG062422; NIH-NINDS U54 NS123985; the Rainwater Charitable Foundation; the Alzheimer's Association; the Global Brain Health Institute; and the Mary Oakley Foundation. This research was supported by the Korea Brain Research Institute basic research program funded by the Ministry of Science and ICT (22-BR-03-05). Funding support for the "Genetic Consortium for Late Onset Alzheimer's Disease" was provided through the Division of Neuroscience, NIA. The Genetic Consortium for Late Onset Alzheimer's Disease includes a genome-wide association study funded as part of the Division of Neuroscience, NIA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of National Institutes of Health gave ethical approval for this work, IRB number: 000699I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode will be made available on the CARD GitHub after peer review: https://github.com/NIH-CARD/ Summary statistics from this study will be available to browse and download via our collaboration with the Broad's Neurodegenerative Disease Knowledge Portal after peer review: https://ndkp.hugeamp.org:8000/